



SciTech Development, LLC

FOR IMMEDIATE RELEASE

SciTech Files Immunotherapeutic Cancer Treatment Patent

(GROSSE POINTE FARMS, MI) December 2, 2018 – SciTech Development is pleased to announce that the law firm Wilson Sonsini Goodrich & Rosati recently filed a provisional patent application entitled “Use of Fenretinide Nanoparticles for Immunotherapeutic Cancer Treatment” on its behalf. Described in the patent application is a method that aids in the treatment of cancer, including cutaneous t-cell lymphoma (CTCL). As an example, a pharmaceutical formulation of the disclosure can treat CTCL by activating the innate immune system of a patient to recognize and destroy cancer cells. This immune mechanism of action (MOA) compliments the already established direct therapeutic effect that fenretinide has in selectively generating programmed cell death (apoptosis or “cellular suicide”) of cancer cells while leaving healthy, non-cancerous cells intact.

This new disclosure places ST-001 in the relatively new, fast-growing immunotherapy category where the majority of new oncology drug development is focused. The likelihood that ST-001 will function as both a safe immune and chemo therapy places it in a unique position to address a broad cross section of cancer indications without any significant side effects.

About SciTech Development

SciTech Development, LLC is a clinical stage, biopharmaceutical company that has developed a unique, immune oncology (IO), intravenously (IV) administered, small molecule, nano-suspension version of the well-known anticancer agent, fenretinide. Fenretinide has been shown, in extensive clinical trials, to be a safe and effective therapeutic drug with targeted cancer destroying activity when blood plasma levels (bioavailability) reach a well-established baseline for several days, an outcome inconsistently realized in the past. This lead product was made possible by SciTech’s discovery of a new delivery system (SciTech Delivery Vehicle - SDV) to enable IV delivery of water-insoluble drugs. The combination of SDV and fenretinide has led to SciTech’s first drug product, ST-001, that holds the promise of improving and saving many lives. SciTech Development is headquartered in the Metropolitan Detroit Michigan Area with laboratories at the Sinai Hospital BioIncubator in Baltimore Maryland. More information regarding SciTech’s nano-delivery technology and oncology drug product ST-001 is available at <https://www.scitechdevelopment.com/>

For More Information: Earle T. Holsapple, President
SciTech Development, LLC
(313) 938-5517



####